Inventor · disambiguated record
Sattva S. Neelapu
Also filed as: NEELAPU SATTVA S
3 granted patents·9 pending applications·1 citations·filing 2012–2023
48Inventor score
Top patents by PatentIndex Score
12 records- 0165US9290541B2TCL1 peptides for immunotherapyUNIV TEXAS·Filed 2012·Granted Mar 22, 2016·1 cites·18 claims
- 0263US2025249038A1Cd30 hinge and/or transmembrane domain-based chimeric antigen receptorsUNIV TEXAS·Filed 2023·Application pending·0 cites
- 0357US2025101113A1Anti-cd94 antibody and chimeric antigen receptor and methods of use thereofUNIV TEXAS·Filed 2023·Application pending·0 cites
- 0456US2025222105A1Anti-rori antibody and chimeric antigen receptor and methods of use thereofUNIV TEXAS·Filed 2023·Application pending·0 cites
- 0555US2024254192A1Chimeric polypeptides and methods of useUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0653US2025161447A1Anti-cd19 and anti-cd79b chimeric antigen receptors and methods of use thereofUNIV TEXAS·Filed 2023·Application pending·0 cites
- 0750US11919937B2T cell receptors for immunotherapyUNIV TEXAS·Filed 2019·Granted Mar 5, 2024·0 cites·19 claims
- 0850US2024084403A1Gut Microbiome as a Predictive Biomarker of Outcomes for Chimeric Antigen Receptor T-Cell TherapyUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0948US2022370495A1Immune cells for adoptive cell therapiesUNIV TEXAS·Filed 2020·Application pending·0 cites
- 1046US12454574B2Anti-CD79B antibodies and chimeric antigen receptors and methods of use thereofUNIV TEXAS·Filed 2019·Granted Oct 28, 2025·0 cites·46 claims
- 1145US2023183371A1Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereofUNIV TEXAS·Filed 2021·Application pending·0 cites
- 1241US2014363456A1Tumor-specific gm-csf cytokine response as predictor of cancer vaccine effectivenessBIOVEST INT INC·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sattva S. Neelapu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →